Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry all, out of the office all day. Hectic day, didn't get time to inform all that I won't be able to update today
Scripts Update for Week Ending 27/10
ATH in TRx & NRx Numbers – 2nd ATH in Refills
V
TRx: 24,780 {vs 24,405; +1.54%} Sector +1.42% -- ATH
NRx: 9,699 {vs 9,398; +3.20%} Sector +1.45% -- ATH
Ref: 15,081 {vs 15,007; +0.49%} Sector +1.40% -- {2nd ATH}
GenL
TRx: 51,538 {vs 50,923; +1.21%}
NRx: 19,571 {vs 19,437; +0.69%}
L
TRx: 3,703 {vs 3,576; +3.55%}
NRx: 1,510 {vs 1,506; +0.27%}
V TRx Market Share: 30.97% vs 30.93% -- {2nd ATH}
V NRx Market Share: 31.51% vs 30.97% -- {2nd ATH}
V Ref Market Share: 30.63% vs 30.90% -- {4th ATH}
Scripts Update for Week Ending 20/10
V
TRx: 24,405 {vs 24,434; -0.12%} Sector -0.21% -- {3rd ATH}
NRx: 9,398 {vs 9,375; +0.25%} Sector +0.47% -- {4th ATH}
Ref: 15,007 {vs 15,059; -0.35%} Sector -0.63% -- {4th ATH}
GenL
TRx: 50,923 {vs 50,866; +0.11%}
NRx: 19,437 {vs 19,179; +1.35%}
L
TRx: 3,576 {vs 3,771; -5.17%}
NRx: 1,506 {vs 1,644; -8.39%}
V TRx Market Share: 30.93% vs 30.90% -- {2nd ATH}
V NRx Market Share: 30.97% vs 31.05%
V Ref Market Share: 30.90% vs 30.81% -- ATH
9M-2017 vs. 9M-2016 (Retail + Inst. Data)
V
TRx 9M-2017 vs 9M-2016 +41.28% – Sector -2.12%
NRx 9M-2017 vs 9M-2016 +41.38% – Sector -0.04%
Ref 9M-2017 vs 9M-2016 +41.23% – Sector -3.21%
Gen L
TRx 9M-2017 vs 9M-2016 -11.08%
NRx 9M-2017 vs 9M-2016 -11.14%
L
TRx 9M-2017 vs 9M-2016 -34.07%
NRx 9M-2017 vs 9M-2016 -5.73%
V 9M-2017 Retail+Inst. TRx Market Share: 27.43% vs 19.01% in 9M-2016
V 9M-2017 Retail+Inst. NRx Market Share: 29.46% vs 20.83% in 9M-2016
V 9M-2017 Retail+Inst. Ref Market Share: 26.33% vs 18.05% in 9M-2016
Q3-2017 vs. Q2-2017 (Retail + Inst. Data)
V
TRx: 333,313 {vs 301,546; +10.53%} – Sector +4.35% --- ATH
NRx: 118,723 {vs 113,911; +4.22%} – Sector +1.21% --- ATH
NRx: 214,590 {vs 187,635; +14.37%} – Sector +6.06% --- ATH
Gen L
TRx: 750,821 {vs 764,592; -1.80%}
NRx: 248,003 {vs 261,672; -5.22%}
L
TRx: 50,138 {vs 20,805; +141%}
NRx: 19,619 {vs 6,158; +219%}
V Q3-2017 Retail+Inst TRx Market Share: 29.39% vs 27.74% in Q2-2017 -- ATH
V Q3-2017 Retail+Inst NRx Market Share: 30.73% vs 29.84% in Q2-2017 -- ATH
V Q3-2017 Retail+Inst Ref Market Share: 28.69% vs 26.61% in Q2-2017 -- ATH
Q3-2017 vs. Q3-2016 (Retail + Inst. Data)
V
TRx: 333,313 {vs 236,767; +40.78%} – Sector +0.49% --- ATH
NRx: 118,723 {vs 88,087; +34.78%} – Sector -0.26% --- ATH
Ref: 214,590 {vs 148,680; +44.33%} – Sector +0.83% --- ATH
Gen L
TRx: 750,821 {vs 854,237; -12.11%}
NRx: 248,003 {vs 288,477; -14.03%}
L
TRx: 50,138 {vs 38,092; +31.62%}
NRx: 19,619 {vs 10,772; +82.13%}
V Q3-2017 Retail+Inst. TRx Market Share: 29.39% vs 20.97% in Q3-2016 -- ATH
V Q3-2017 Retail+Inst. NRx Market Share: 30.73% vs 22.74% in Q3-2016 -- ATH
V Q3-2017 Retail+Inst. Ref Market Share: 28.69% vs 20.04% in Q3-2016 -- ATH
Sep-2017 vs. Sep-2016 (Retail + Inst. Data)
V
TRx: 110,260 {vs 79,615; +38.49%} – Sector -1.05% -- 2nd ATH
NRx: 38,690 {vs 29,758; +30.02%} – Sector -3.37% -- 5th ATH
Ref: 71,570 {vs 49,857; +43.55%} – Sector +0.19% -- 2nd ATH
Gen L
TRx: 239,343 {vs 279,313; -14.31%}
NRx: 79,051 {vs 96,047; -17.70%}
L
TRx: 17,889 {vs 12,460; +43.57%}
NRx: 7,069 {vs 3,358; +110.51%}
V Sep-2017 Retail+Inst. TRx Market Share: 30.00% vs 21.44% in Sep -2016 - ATH
V Sep-2017 Retail+Inst. NRx Market Share: 31.00% vs 23.04% in Sep -2016 - ATH
V Sep-2017 Retail+Inst. Ref Market Share: 29.49% vs 20.58% in Sep -2016 – ATH
Total Monthly Retail + Institutional Data September-2017
GROWTH IN INSTITUTIONAL NUMBERS CONTINUES. LARGE ESTABLISHMENTS (ie Hospitals…etc) TAKING NOTICE 3MONTH IN A ROW NOW…
V
TRx: 110,260 {vs 115,227; -4.31%} -- Sector -6.41% --- 2nd ATH
(Inst # 8,150 vs 8,027; +1.53% -- ATH -- Inst Sec -6.11% -- Inst Mkt Sh 24.03% vs 22.22% ATH)
NRx: 38,690 {vs 41,811; -7.46%} – Sector -8.05% -- 5th ATH
Ref: 71,570 {vs 69,604; -2.51%} – Sector -5.55% -- 2nd ATH
Gen L
TRx: 239,343 {vs 257,080; -6.90%}
(Inst # 25,133 vs 27,310; -7.97%)
NRx: 79,051 {vs 85,612; -7.66%}
L
TRx: 17,889 {vs 20,361; -2.51%}
(Inst # 639 vs 792; -19.32%)
NRx: 7,069 {vs 8,310; -14.93%}
V Monthly Retail + Inst. TRx Market Share: 30.00% vs 29.34% --- ATH
V Monthly Retail + Inst. NRx Market Share: 31.00% vs 30.80% --- ATH
V Monthly Retail + Inst. Ref Market Share: 29.49% vs 28.57% --- ATH
Bolio,
CJR_MS numbers for L & GL, i guess he was mistaken for GenL numbers with the whole GL&L combined. If you check his GL numbers, they are the total of my numbers (GL+L) ---> 50,866 + 3,771 = 54,637 & 19,179 + 1,644 = 20,823
Result of this it will increase the total market numbers and decrease market share of V
As for V numbers, i double and triple checked them and i have no clue where did CJR got his numbers. Usually he's always posting the correct ones
Scripts Update for Week Ending 13/10
V
TRx: 24,434 {vs 24,344; +0.37%} Sector -1.44% -- 2nd ATH
NRx: 9,375 {vs 9,266; +1.18%} Sector +0.27% -- 5th ATH
Ref: 15,059 {vs 15,078; -0.13%} Sector -2.47% -- 3rd ATH
GenL
TRx: 50,866 {vs 52,066; -2.30%}
NRx: 19,179 {vs 19,263; -0.44%}
L
TRx: 3,771 {vs 3,815; -1.15%}
NRx: 1,644 {vs 1,587; +3.59%}
V TRx Market Share: 30.90% vs 30.34% -- 2nd ATH
V NRx Market Share: 31.05% vs 30.77% -- 7th ATH
V Ref Market Share: 30.81% vs 30.09% -- ATH
Sorry all, out of the office. Won't be able to update till Tuesday
So for 9M running data in 2017, V numbers are positive and > 41% vs the 9M in 2016, while the market is flat....
I guess this says it all and answer all the concern of few on this board regarding: "plateauing - peaked numbers ....etc"
At the request of rafunrafun; MIC DROP !!
9M-2017 vs. 9M-2016 (Retail only Data)
V
TRx 9M-2017 vs 9M-2016 +41.96% – Sector -0.87%
NRx 9M-2017 vs 9M-2016 +41.38% – Sector -0.04%
Ref 9M-2017 vs 9M-2016 +42.34% – Sector -0.75%
Gen L
TRx 9M-2017 vs 9M-2016 -11.33%
NRx 9M-2017 vs 9M-2016 -11.14%
L
TRx 9M-2017 vs 9M-2016 -12.64%
NRx 9M-2017 vs 9M-2016 -5.73%
V 9M-2017 Retail Only TRx Market Share: 28.23% vs 19.72% in 9M-2016 - ATH
V 9M-2017 Retail Only NRx Market Share: 29.46% vs 20.83% in 9M-2016 - ATH
V 9M-2017 Retail Only Ref Market Share: 27.47% vs 19.15% in 9M-2016 - ATH
Q3-2017 vs. Q2-2017 (Retail ONLY Data)
V
TRx: 309,980 {vs 287,124; +7.96%} – Sector +2.65% --- ATH
NRx: 118,723 {vs 113,911; +4.22%} – Sector +1.21% --- ATH
NRx: 191,257 {vs 173,213; +10.42%} – Sector +3.53% --- ATH
Gen L
TRx: 672,980 {vs 698,830; -3.70%}
NRx: 248,003 {vs 261,672; -5.22%}
L
TRx: 47,832 {vs 18,262; +161%}
NRx: 19,619 {vs 6,158; +219%}
V Q3-2017 Retail ONLY TRx Market Share: 30.07% vs 28.59% in Q2-2017 – ATH
V Q3-2017 Retail ONLY NRx Market Share: 30.73% vs 29.84% in Q2-2017 -- ATH
V Q3-2017 Retail ONLY Ref Market Share: 29.68% vs 27.83% in Q2-2017 -- ATH
Q3-2017 vs. Q3-2016 (Retail ONLY Data)
V
TRx: 309,980 {vs 225,955; +37.19%} – Sector -0.79% --- ATH
NRx: 118,723 {vs 88,087; +34.78%} – Sector -0.26% --- ATH
Ref: 191,257 {vs 137,868; +38.72%} – Sector -1.11% --- ATH
Gen L
TRx: 672,980 {vs 784,750; -14.24%}
NRx: 248,003 {vs 288,477; -14.03%}
L
TRx: 47,832 {vs 28,315; +68.93%}
NRx: 19,619 {vs 10,772; +82.13%}
V Q3-2017 Retail ONLY TRx Market Share: 30.07% vs 21.75% in Q3-2016 -- ATH
V Q3-2017 Retail ONLY NRx Market Share: 30.73% vs 22.74% in Q3-2016 -- ATH
V Q3-2017 Retail ONLY NRx Market Share: 29.68% vs 21.16% in Q3-2016 -- ATH
Sep-2017 vs. Sep-2016 (Retail ONLY Data)
V
TRx: 102,110 {vs 76,629; +33.25%} – Sector -3.14%
NRx: 38,690 {vs 29,758; +30.02%} – Sector -3.37%
Ref: 63,420 {vs 46,871; +35.31%} – Sector -3.00%
Gen L
TRx: 214,210 {vs 258,650; -17.18%}
NRx: 79,051 {vs 96,047; -17.70%}
L
TRx: 17,250 {vs 9,110; +89.35%}
NRx: 7,069 {vs 3,358; +110.51%}
V Sep-2017 Retail ONLY TRx Market Share: 30.61% vs 22.25% in Sep -2016 - ATH
V Sep-2017 Retail ONLY NRx Market Share: 31.00% vs 23.04% in Sep -2016 - ATH
V Sep-2017 Retail ONLY Ref Market Share: 30.38% vs 21.78% in Sep -2016 - ATH
Total Monthly Retail ONLY Data September-2017
ATH Across the Board in Market Share
V
TRx: 102,110 {vs 107,200; -4.75%} – Sector -6.44%
NRx: 38,690 {vs 41,811; -7.46%} – Sector -8.05%
Ref: 63,420 {vs 65,389; -3.01%} – Sector -5.46%
Gen L
TRx: 214,210 {vs 229,770; -6.77%}
NRx: 79,051 {vs 85,612; -7.66%}
L
TRx: 17,250 {vs 19,569; -11.85%}
NRx: 7,069 {vs 8,310; -14.93%}
Monthly Retail TRx Market Share: 30.61% vs 30.07% --- ATH
Monthly Retail NRx Market Share: 31.00% vs 30.80% --- ATH
Monthly Retail Refills Market Share: 30.38% vs 29.61% --- ATH
Scripts Update for Week Ending 06/10
V
TRx: 24,344 {vs 24,339; +0.02%} Sector +2.18% -- 2nd ATH
NRx: 9,266 {vs 9,394; -1.36%} Sector +1.37%
Ref: 15,078 {vs 14,945; +0.89%} Sector +2.67% -- 2nd ATH
GenL
TRx: 52,066 {vs 50,143; +3.84%}
NRx: 19,263 {vs 18,621; +3.45%}
L
TRx: 3,815 {vs 4,032; -5.38%}
NRx: 1,587 {vs 1,694; -6.32%}
V TRx Market Share: 30.34% vs 31.00%
V NRx Market Share: 30.77% vs 31.62%
V Ref Market Share: 30.09% vs 30.62%
Hondo
Both July & August 2017 were > 100K
July-2017: 100,670 (Retail) // 107,826 (Retail + Institutional)
August-2017: 107,200 (Retail) // 115,227 (Retail + Institutional)
Scripts Update for Week Ending 29/09
ATH in TRx & NRx Market Share
V
TRx: 24,339 {vs 24,604; -1.08%} Sector -1.44% -- {2nd ATH}
NRx: 9,394 {vs 9,431; -0.39%} Sector -1.65% -- {4th ATH}
Ref: 14,945 {vs 15,173; -1.50%} Sector -1.31% -- {2nd ATH}
GenL
TRx: 50,143 {vs 50,900; -1.49%}
NRx: 18,621 {vs 19,051; -2.26%}
L
TRx: 4,032 {vs 4,159; -3.05%}
NRx: 1,694 {vs 1,726; -1.85%}
V TRx Market Share: 31.00% vs 30.89% -- ATH
V NRx Market Share: 31.62% vs 31.22% -- ATH
V Ref Market Share: 30.62% vs 30.68% -- {2nd ATH}
What We Learn When Two Ruthless Killers, Heart Disease and Cancer, Reveal a Common Root
Apologies if it was posted before
https://www.nytimes.com/2017/09/27/magazine/can-heart-disease-shed-light-on-cancer.html
Posted by Lawleycpa on ST
" Two cardiologists, Peter Libby and Paul Ridker, were thinking about plaque formation in a different way. Libby and Ridker acknowledged the role of cholesterol and lipids. But just as important was another variable, seldom discussed: inflammation — the recruitment and activation of certain immune cells. These activated immune cells infiltrated blood vessels early in the course of coronary disease and enabled plaques to grow and rupture. “Bad” cholesterol was a necessary part of the equation — it was these lipid deposits that may incite the immune cells, they proposed — but it was not sufficient."
"If inflammation triggers coronary disease, might targeting it directly — beyond simply reducing cholesterol — decrease the risk of heart attacks? Over the course of a decade, Libby and Ridker found themselves focusing on a molecule involved in inflammation called interleukin-1 beta. By the mid-2000s, they heard of a new drug — an interleukin-1-beta inhibitor — that was used to treat exceedingly rare inflammatory diseases"
"The results, published this August, are provocative: Despite no change in cholesterol levels, there was a demonstrable reduction in heart attacks, stroke and cardiovascular death, particularly at higher doses of the drug. But what caught my attention was a separate analysis that asked a seemingly unrelated question: Might the drug also reduce the risk of cancer? In a paper published in The Lancet, Ridker and his colleagues found that drug-treated patients had a drop in all cancer mortality."
Scripts Update for Week Ending 22/09
ATH in TRx & Refills --- NRx so close to ATH
V
TRx: 24,604 {vs 24,076; +2.19%} Sector +1.65% -- ATH
NRx: 9,431 {vs 9,302; +1.39%} Sector +1.14% -- 3rd ATH
Ref: 15,173 {vs 14,774; +2.70%} Sector +1.97% -- ATH
GenL
TRx: 50,900 {vs 50,102; +1.59%}
NRx: 19,051 {vs 18,826; +1.20%}
L
TRx: 4,159 {vs 4,189; -0.72%}
NRx: 1,726 {vs 1,740; -0.80%}
V TRx Market Share: 30.89% vs 30.72% -- ATH
V NRx Market Share: 31.22% vs 31.14% -- 4th ATH
V Ref Market Share: 30.68% vs 30.46% -- ATH
Scripts Update for Week Ending 15/09
Good Numbers taking into consideration the hurricane / storm
V
TRx: 24,076 {vs 23,022; +4.58%} Sector +1.54% -- 3rd ATH
NRx: 9,302 {vs 8,227; +13.07%} Sector +8.78% -- 4th ATH
Ref: 14,774 {vs 14,795; -0.14%} Sector -2.46% -- 4th ATH
GenL
TRx: 50,102 {vs 50,251; -0.30%}
NRx: 18,826 {vs 17,778; +5.89%}
L
TRx: 4,189 {vs 3,905; +7.27%}
NRx: 1,740 {vs 1,453; +19.75%}
V TRx Market Share: 30.72% vs 29.83% -- ATH
V NRx Market Share: 31.14% vs 29.96% -- 4th ATH
V Ref Market Share: 30.46% vs 29.76% -- ATH
FFS
i am not shouting, didn't realize my Caps Lock was on
you say " I am only focusing on what happens to the trend post continuation as consumers, patients, PCPs, Cardiologists..."
Well the numbers posted include more than one week post continuation and they are still increasing...month to month is more accurate i would say....anyhow to answer the above, the most accurate will be Institutional numbers and those are also up more than 12% post continuation....
you turn it the way you want, how it suits your agenda....i don't care, do whatever you want, but be transparent, that's all i'm asking
Institutional Sales Channels: Drug Sales into Hospitals, Doctor’s Offices, Dialysis Clinics, Long-Term Health Facilities, Prisons
and those are +107.68% (8,027 vs 3,865) from April-2017 till August-2017....yup i would say they do realize V doesn't work and that's why they are not prescribing it .... come one, give me a break !!!!
FFS --- Declining Scripts
MMMMMM I'LL LEAVE YOU TO THE 2 MSGS I POSTED EARLIER AND I AM LOOKING FWD TO SEE HOW UR GONNA TURN THINGS AROUND
THX FOR THE LAUGH IN ADVANCE
ALL THE BEST :)
Aug-2017 vs. Aug-2016(Retail + Inst Data)
V
TRx: 115,227 {vs 81,932; +40.64%} – Sector +0.99% -- ATH
NRx: 41,811 {vs 30,981; +34.96%} – Sector +0.48% -- ATH
Ref: 73,416 {vs 50,951; +44.09%} – Sector +1.26% -- ATH
Gen L
TRx: 257,080 {vs 293,100; -12.29%}
NRx: 85,612 {vs 100,370; -14.70%}
L
TRx: 20,361 {vs 13,799; +47.55%}
NRx: 8,310 {vs 3,739; +122.25%}
V Aug-2017 Retail + Inst TRx Market Share: 29.34% vs 21.07% in Aug -2016 -- ATH
V Aug -2017 Retail + Inst NRx Market Share: 30.80% vs 22.93% in Aug -2016 -- ATH
V Aug -2017 Retail + Inst Ref Market Share: 28.57% vs 20.08% in Aug -2016 -- ATH
Total Monthly Retail + Institutional Data August-2017
GREAT INSTITUTIONAL NUMBERS CONTINUE. LARGE ESTABLISHMENTS (ie Hospitals…etc) FINALLY TAKING NOTICE 2M IN A ROW NOW…
V
TRx: 115,227 {vs 107,826; +6.86%} -- Sector +4.96% --- ATH
(Inst # 8,027 vs 7,156; +12.17% -- ATH -- Inst Sec +8.08% -- Inst Mkt Sh 22.22% vs 21.41% ATH)
NRx: 41,811 {vs 38,222; +9.39%} – Sector +7.89% -- ATH
Ref: 73,416 {vs 69,604; +5.48%} – Sector +3.47% -- ATH
Gen L
TRx: 257,080 {vs 254,398; +1.05%}
(Inst # 27,310 vs 25,398; +7.53%)
NRx: 85,612 {vs 83,340; +2.73%}
L
TRx: 20,361 {vs 11,888; +71.27%}
(Inst # 792 vs 875; -9.49%)
NRx: 8,310 {vs 4,240; +95.99%}
V Monthly Retail + Inst. TRx Market Share: 29.34% vs 28.82% --- ATH
V Monthly Retail + Inst. NRx Market Share: 30.80% vs 30.39% --- ATH
V Monthly Retail + Inst. Ref Market Share: 28.57% vs 28.03% --- ATH
Scripts Update for Week Ending 08/09
Short Week
V
TRx: 23,022 {vs 23,536; -2.18%} Sector -2.96%
NRx: 8,227 {vs 8,939; -7.97%} Sector -8.29%
Ref: 14,795 {vs 14,597; +1.36%} Sector +0.26%
GenL
TRx: 50,251 {vs 51,617; -2.65%}
NRx: 17,778 {vs 19,104; -6.94%}
L
TRx: 3,905 {vs 4,380; -10.84%}
NRx: 1,453 {vs 1,898; -23.45%}
V TRx Market Share: 29.83% vs 29.59%
V NRx Market Share: 29.96% vs 29.86%
V Ref Market Share: 29.76% vs 29.43%
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer.
Recruiting Salyer from Teva Pharmaceuticals... Interesting.
Most recently, Mark W. Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC
FFS,
So 2 bad back to back weeks which is ~ 50% of August Month yet the Total Numbers of August is POSITIVE +6.50% vs July and POSITIVE +36.50% vs a Year ago !!!!
mmmmmm, excuse me, but i am trying to understand your logic, but it ain't happening to me, i must be a slow learner
Please shoot and educate me regarding the Logic you use.
Much appreciated in advance
Aug-2017 vs. Aug-2016 (Retail ONLY Data)
V
TRx: 107,200 {vs 78,534; +36.50%} – Sector -0.99%
NRx: 41,811 {vs 30,981; +34.96%} – Sector +0.48%
Ref: 65,389 {vs 47,553; +37.51%} – Sector -1.87%
Gen L
TRx: 229,770 {vs 271,700; -15.43%}
NRx: 85,612 {vs 100,370; -14.70%}
L
TRx: 19,569 {vs 9,879; +98.09%}
NRx: 8,310 {vs 3,739; +122.25%}
V Aug-2017 Retail ONLY TRx Market Share: 30.07% vs 21.81% in Aug -2016
V Aug -2017 Retail ONLY NRx Market Share: 30.80% vs 22.93% in Aug -2016
V Aug -2017 Retail ONLY Refills Market Share: 29.61% vs 21.13% in Aug -2016
Total Monthly Retail ONLY Data August-2017
ATH Across the Board in Market Share & Number
V
TRx: 107,200 {vs 100,670; +6.49%} – Sector +4.65% -- ATH
NRx: 41,811 {vs 38,222; +9.39%} – Sector +7.89% -- ATH
Ref: 65,389 {vs 62,448; +4.71%} – Sector +2.76% -- ATH
Gen L
TRx: 229,770 {vs 229,000; +0.34%}
NRx: 85,612 {vs 83,340; +2.73%}
L
TRx: 19,569 {vs 11,013; +77.69%}
NRx: 8,310 {vs 4,240; +95.99%}
Monthly Retail TRx Market Share: 30.07% vs 29.55% --- ATH
Monthly Retail NRx Market Share: 30.80% vs 30.39% --- ATH
Monthly Retail Refills Market Share: 29.61% vs 29.06% --- ATH
August Numbers - FFS & All,
I am sorry, my prediction was not accurate :(:(
I predicted ~ 2% - 3% increase in numbers, it turned out that i was super wrong
August Retail TRx is +6.50% & NRx +9.40% & Ref +4.70%
ALL ATH Numbers
Will post the numbers in due time & Sorry FFS & Co for not being accurate with my predictions, but hey you know one or two thing about missed predictions :):)
FFS & ALL,
24hrs ain't too long.
Tomorrow i will be posting the monthly Retail TRx & NRx numbers for the month of August-2017 with a comparison to July-2017 & August-2016
Institutional Numbers will be posted mid of next week and we will see if there is a continuation in terms of huge jump in Inst. numbers as last month (Last month Inst numbers increased by +36.20%)
(A quick recap, Inst. Sales Channels = Drug sales into hospitals, doctor’s offices, dialysis clinics, Long-term health facilities, prisons.)
Just by looking at the weekly numbers and those are not that accurate as months overlap, if my estimation is correct we should be like > ~ +2%-3%% month to month and > ~ +35% vs August-2016
So let's not discuss TRx no more. Making assumption in order to fit X, Y or Z agenda is easily considered as misguidance
The best thing in numbers is that NUMBERS NEVER LIE and the numbers will be available tmw :)
Scripts Update for Week Ending 01/09
V
TRx: 23,536 {vs 23,971; -1.81%} Sector +0.28%
NRx: 8,939 {vs 9,133; -2.12%} Sector +0.31%
Ref: 14,597 {vs 14,838; -1.62%} Sector +0.25%
GenL
TRx: 51,617 {vs 50,938; +1.33%}
NRx: 19,104 {vs 18,892; +1.12%}
L
TRx: 4,380 {vs 4,405; -0.57%}
NRx: 1,898 {vs 1,823; +4.11%}
V TRx Market Share: 29.59% vs 30.22%
V NRx Market Share: 29.86% vs 30.60%
V Ref Market Share: 29.43% vs 30.00%
Scripts Update for Week Ending 25/08
V
TRx: 23,971 {vs 24,088; -0.49%} Sector +0.16% -- 2nd ATH
NRx: 9,133 {vs 9,433; -3.18%} Sector -0.61% -- 6th ATH
Ref: 14,838 {vs 14,655; +1.25%} Sector +0.63% -- ATH
GenL
TRx: 50,938 {vs 50,566; +0.74%}
NRx: 18,892 {vs 18,656; +1.27%}
L
TRx: 4,405 {vs 4,533; -2.82%}
NRx: 1,823 {vs 1,943; -6.18%}
V TRx Market Share: 30.22% vs 30.42% -- 2nd ATH
V NRx Market Share: 30.60% vs 31.41% -- 6th ATH
V Ref Market Share: 30.00% vs 29.81% -- ATH
Whal,
Yup that will be done as soon as August Monthly Numbers are out.
A quick comparison below;
4 Data Weekly Numbers;
1) Week ending 5-Aug-16 till Week ending 26-Aug-16 = 69,025
2) Week ending 4-Aug-17 till Week ending 25-Aug-17 = 98,829
2 vs 1 = +38.83%
4 Data Weekly Numbers;
1) Week ending 7-July-17 till Week ending 28-July-17 = 92,430
2) Week ending 4-Aug-17 till Week ending 25-Aug-17 = 98,829
2 vs 1 = +6.92%
The above are weekly numbers, but mentioned it just to show you that we are still growing :):)
Whal, REPLY #2
Looking at my previous post, you can conclude the following;
1) 2017 Numbers till July = 677,812
2) 2016 Numbers till July = 477,806
3) 2016 Full Year Numbers = 895,724
So up till July (included);
* we reached 75.67% of Full 2016 Numbers with 5 month left till year end
* we are +41.86% compared to 2016 numbers (Jan to July)
Whal,
below are monthly change in total scripts since Jan-2015 (including Inst. numbers). You need to look at the bigger picture of month to month variation and quarter by quarter. As can be seen from my earlier posts, we are still having a change > 40% each quarter compared to 2016 numbers :):) ;
Jan-15 // 39,695 // -7.31%
Feb-15 // 38,614 // -2.72%
Mar-15 // 44,354 // 14.87%
Apr-15 // 44,324 // -0.07%
May-15 // 45,966 // 3.70%
Jun-15 // 49,301 // 7.26%
Jul-15 // 51,206 // 3.86%
Aug-15 // 52,940 // 3.39%
Sep-15 // 54,344 // 2.65%
Oct-15 // 58,158 // 7.02%
Nov-15 // 58,583 // 0.73%
Dec-15 // 64,159 // 9.52%
Jan-16 // 58,265 // -9.19%
Feb-16 // 60,526 // 3.88%
Mar-16 // 68,440 // 13.08%
Apr-16 // 67,961 // -0.70%
May-16 // 72,269 // 6.34%
Jun-16 // 75,125 // 3.95%
Jul-16 // 75,220 // 0.13%
Aug-16 // 81,932 // 8.92%
Sep-16 // 79,615 // -2.83%
Oct-16 // 82,919 // 4.15%
Nov-16 // 83,218 // 0.36%
Dec-16 // 90,234 // 8.43%
Jan-17 // 86,096 // -4.59%
Feb-17 // 83,367 // -3.17%
Mar-17 // 98,977 // 18.72%
Apr-17 // 93,522 // -5.51%
May-17 // 103,700 // 10.88%
Jun-17 // 104,324 // 0.60%
Jul-17 // 107,826 // 3.36%